

Cell & Gene Therapy Bioprocessing & Commercialization

September 4-7, 2018
Hynes Convention Center
Boston, MA



TRANSFORMING INNOVATIVE RESEARCH TO DRIVE THE FUTURE OF CELL & GENE THERAPY MANUFACTURING AND COMMERCIALIZATION

Real-World Insights. Trusted Resources. Novel Solutions.



50+

New companies attended in 2017 –
Were you one of them?



300+

Attendees hit Boston in 2017 -
This year will be bigger and better



70:30

Buyer:Seller Ratio

Part of **Biotech Week**
Boston

BIOPROCESSING:

- Investigate monitoring quality across your process with PAT, QbD and novel analytical methods
- Get top tips on the application of process automation and closed systems in manufacturing
- Dive into costs of goods calculations and considerations

COMMERCIALIZATION:

- Making the decision to either insource or outsource manufacturing? What's the best choice?
- Hear the latest on designing a manufacturing facility to meet scaling up and out requirements
- Put yourself in the shoes of Novartis or Kite – a retrospective look at 2017



CLINICAL:

- Get the latest on current development pipelines –optimise preclinical models and examine novel targets
- Pick up knowledge on pre-clinical regulatory and process considerations for entering the clinic
- Push the boundaries of collaboration for end-to-end solutions in preclinical and clinical research

LOGISTICS, SUPPLY CHAIN, AND CRYOPRESERVATION:

- Immerse yourself in cryopreservation – considerations when moving from clinical phase to commercial
- Understand vein-to-vein supply chain and transportation strategies
- Master chain of identity, analytical considerations and patient specific batches

CUTTING EDGE CASE STUDIES AND UN-RIVALLED BENCHMARKING OPPORTUNITIES

- **The Evolution of Analytics in CAR-T Cell Therapy**
Tariq Warsi, Senior Scientist, Process Development, **Amgen, USA**
- **A Forward Look at the Future of Cell Therapy Manufacturing**
Donna Rill, Vice President of Manufacturing, **Cell Medica Inc**
- **New Analytical Technologies for Facilitating Qbd in Process Analytics**
Junxia Wang, Director, Analytical Development, **Mustang Bio Inc., USA**
- **Implementation of an Affordable and Scalable Manufacturing Strategy**
Jon Gunther, Associate Director Technology Strategy and Innovation, **Juno Therapeutics, USA**
- **T Lymphocyte Targeting Strategies: CAR-T and TCR-T Success Challenges and Path Forward**
Miguel Forte, CEO, **Zelluna Immunotherapy, Norway**
- **Combination of Analytical Methods for Characterization of Viral Vectors**
Gillian Payne, Director, Vector Analytics, **bluebird bio, USA**
- **What Academia are Looking for in a Development Partner**
Olive J Sturtevant, Administrative Director of Connell & O'Reilly Families, Cell Manipulation Core Facility, **Dana Farber Cancer Institute**
- **Current State of Play for the Cell Therapy Industry in the Clinic – Stats and Facts**
Patricia Reilly, Head of Intelligence Alliances and Unification, Pharma Intelligence, **Informa, USA**
- **Leveraging Academic and Commercial Contract Manufacturing Organizations to Facilitate Accelerated FDA Approvals**
Linda Kelley, Senior Member, Director Cell Therapy Facility, **Moffitt Cancer Center, USA**
- **The Economics of Closed Systems – Ensuring Reproducibility**
Ohad Karnieli, CEO & Co-Founder, **ATVIO Biotech, Israel**
- **Ensuring Enough Supply and Magnitude in Terms of Patient and Dose Increases**
Someet Narang, Senior Scientist, **MedImmune, USA**
Wouter Van t'Hof, Cord Blood Bank Director, **Cleveland Cord Blood Centre, USA**
- **It Depends: Understanding the Science and History behind the Regulations**
Nancy Markovitz, Assoc. Director, Regulatory Affairs CMC, **Nantkwest, USA**
- **Breakfast Surgery – FDA, EMA and PMDA Pinch Points**
- **The Next Wave of Cell Therapy Product – Allogeneic Manufacturing Solutions**
Yajin (Jenny) Ni, Associate Research Fellow, Director Manufacturing Process Development Lead, **Allogene Therapeutics, Inc., USA**
- **Delivering New Investigational Medicinal Products to the Clinic Through Next-Generation Allogeneic Cell Therapies**
Bryan D. Utter, Procurement Manager, GMP Solutions, **Collectis Inc., USA**
- **Developing a Commercially-Ready Process for Viral Vector Manufacturing**
John Kerwin, Manufacturing Scientist, Gene Therapy, **Biogen, USA**
- **Current State of Play for the Cell Therapy Industry in the Clinic – Stats and Facts**
Patricia Reilly, Head of Intelligence Alliances and Unification, Pharma Intelligence, **Informa, USA**
- **What Academia are Looking for in a Development Partner**
Olive J Sturtevant, Administrative Director of Connell & O'Reilly Families, Cell Manipulation Core Facility, **Dana Farber Cancer Institute**
- **CASE STUDY: Adaptimmune – SPEAR T-cells**
Dan Williams, VP Research and Technology Operations, **Adaptimmune, UK**
- **CASE STUDY: Key Success Factors for Planning and Building a Facility for Cell Therapies**
Knut Niss, Chief Technology Officer, **Mustang Bio, USA**
- **CASE STUDY: Low Cost Automation to Drive Efficiency and Reproducibility**
Shashi Murthy, Professor of Chemical Engineering, **Northeastern University, USA**
- **PANEL: What Can Be Learned from those Already Manufacturing at Commercial Scale**
- **PANEL: What Can Cell Therapy Manufacturers Learn from MAbs to Save Time and Money on the Path to Commercial Scale Manufacturing**
Trent Munro, Executive Director, Process Development, **Amgen Inc., USA**
Lan Cao, Senior Director, Cell Therapy Head of Product Development and Clinical Manufacturing, **Takeda Pharmaceuticals International Co., USA**
- **PANEL: Driving Collaboration for Development In Cell and Gene Therapy**
- **PANEL: CDMO Experts: How Do You Choose Your Development Partner?**

Pre-Conference Workshops • Tuesday, September 4, 2018 • 9.00 - 6.00pm or 12:00 - 6:00pm

 Workshop 1: Raw Materials Focus Day	 Workshop 2: Process Development and Manufacturing Scale Up for Engineered Tissues	 Workshop 3: Cell & Gene Connect – Partnering Track
<p><i>Topics to be covered include:</i></p> <ul style="list-style-type: none"> • Elimination of variations, especially in starting and raw materials/ ancillary materials and manual manufacturing steps • GMP-grade raw materials • Regulatory guidance surrounding raw materials - USP Chapter <1043>, <92> and EMA's Ph. Eur. General Chapter 5.2.12 • Automated systems linked to the removal of variation in raw materials • Developments in manufacturing augmenting a greater need for higher quality raw materials and customised raw materials • Assessment of origin and impurity profiles • Best practise for providing documented evidence of purity, potency, consistency and stability • Supplier agreements and ensuring sufficient supply chain for large scale commercial manufacturing • Analytical testing <p>Omer Butt, Director, CMC Regulatory Affairs, Athersys, Inc., USA</p> <p>Mithu Majumder, Project Manager, RoosterBio Inc., USA</p> <p>Rosemary Versteegen, CEO, ISIA, USA</p>	<p>12:00 <i>Registration</i></p> <p>1:00 Chairperson's Opening Remarks Tom Bollenbach, Ph.D., Chief Technology Officer, Advanced Regenerative Manufacturing Institute</p> <p>1:15 Keynote Address – Engineered Tissue Manufacturing: Lessons Learned from Large Scale Commercialization Katie Faria, Director of Product and Process Development, Organogenesis</p> <p>1:45 Regulatory Considerations for Tissue Engineered Product Development Yong Fan, Senior Consultant, A2Z Reg Solutions, USA</p> <p>2:15 Multi-platform-based Characterization of Cell Products and Processes: Identification of CQAs and Application of QbD Principles Carolyn Yeago, Assoc. Director of Research, Marcus Center for Therapeutic Cell Characterization and Manufacturing, Georgia Institute of Technology, USA</p> <p>2:45 Role of Data Management and Artificial Intelligence in Automation of Biomanufacturing Process Development</p> <p>3:15 <i>Networking Refreshment Break</i></p> <p>3:45 Integrated, Closed System PAT Analytics for Advanced Auto Feedback Control of CPPs in Single Use Bioreactors – Reactive Analytics</p> <p>4:15 Automation and Robotics in Large-Scale Engineered Tissue Manufacturing</p> <p>4:45 Adherent Cell Manufacturing Matters: Production Platform and Media Strategies Drives Cell Production Economics Jon A. Rowley, Chief Executive & Technology Officer, RoosterBio Inc.</p> <p>5:15 Panel Discussion – Title TBD</p> <p>5:50 Chairperson's Closing Remarks and Look Ahead</p> <p>6:00 <i>Reception</i></p>	<p>9:00 <i>Continental Breakfast</i></p> <p>10:00 Evolving Landscape of Cell & Gene Therapies Patricia Reilly, Head of Intelligence Alliances & Product Unification, Pharma intelligence informa Morrie Ruffin, Co-Founder and Senior Advisor, Adjuvant Partners</p> <p>11:30 Panel Discussion: New Partnering Models: R&D, Hospitals, Manufacturer Boro Dropulic, Chief Scientific Officer & General Manager, Lentigen Technology, Inc A Miltenyi Company Michelle Berg, Vice-President, Patient Affairs and Community Engagement, Abeona Walter Kowtoniuk, Global Genes Advisor and Principal, Third Rock Ventures</p> <p>12:30 Lunch Presentations</p> <p>1:30 Panel Discussion: Public/Private Partnerships Issi Rozen, Chief Business Officer, Broad Institute Dan Gincel, Executive Director, Maryland Stem Cell Research Fund</p> <p>2:30 Panel Discussion: Market Access <i>Moderator: Amanda Micklus, Principal Analyst, Datamonitor Healthcare</i> <i>Panelists:</i> FDA: Rachael Anatol, Ph.D., Deputy Director, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation (Pending) Martha Rook, Head of Gene Editing and Novel Modalities, MilliporeSigma / EMD Millipore</p> <p>3:45 Presentations</p> <p>5:00 Panel Discussion: Next Generation Therapies <i>Moderator: Jessica Carmen, Director of Business Development, Cellular Therapies, MaxCyte, Inc.</i> Sarah Haecker Meeks, VP Business Development, Synpromics, Ltd Michael Nowak, Navan Technology</p> <p>6:00 <i>Reception</i> Partnering meetings will take place from 11:30 am - 6:00 pm</p>



AN EVENING OF DIVERSITY AND INCLUSION

September 4 from 6pm-8pm • Hilton Back Bay Hotel

Speakers: **Edie Stringfellow**, Director of Diversity and Inclusion at **MassBio**
Ramsey Johnson, Founder at **OUTBio**

Connect with leaders who are ready to accelerate a culture of diversity and inclusion in life sciences. View the full program at <https://lifesciences.knect365.com/diversity-inclusion/>. Separate registration required to attend.




7:00	<i>Registration and Coffee</i>		
	PLENARY SESSION		
8:00	Chairperson's Remarks Miguel Forte, CEO, Zelluna Immunotherapy, Norway		
	Beyond First Generation CAR-Ts - Manufacturing Gene-Edited CAR-Ts, NK Cells and TCRs		
8:05	ARM State of the Industry Update Jane Lynch Lambert, CEO, Alliance of Regenerative Medicine		
8:35	CASE STUDY: Adaptimmune – SPEAR T-cells • Case study on TCR candidates Dan Williams, VP Research and Technology Operations, Adaptimmune, UK		
9:05	PANEL DISCUSSION: What Can Be Learned from those Already Manufacturing at Commercial Scale • What is the next big thing beyond CD19? • How do manufacturing strategies differ for solid tumours, NK cells, TCR's as opposed to CAR-T • Is investment in the market too focussed on CAR-T? Is it neglecting other therapies?		
	Spotlight Presentation		
9:25	Use this event to raise your corporate profile and demonstrate your products and services to our targeted, multidisciplinary audience. By joining us in sponsoring and exhibiting at this event, you will be able to: <ul style="list-style-type: none"> • Use an exhibition stand to meet new clients in the main networking area • Raise your corporate profile and shape your corporate image with logo placement • Ensure market presence as a thought leader with a speaking position For sponsorship and exhibition opportunities please contact: Jennifer Wickett, Tel: +1 857 504 6694; Email: jennifer.wickett@knect365.com		
9:45	<i>Networking Refreshment Break in the Biotech Week Boston Poster & Exhibit Hall</i>		
	Bioprocessing	Commercialization	Pre-clinical and Clinical Development
10:10	Chairperson's Remarks	Chairperson's Remarks	Chairperson's Remarks Ken LeClair, VP, Technical Development and Manufacturing, Editad Medicine, USA
	Monitoring Quality Across the Process – Process and Automated Analytics for Cell Therapies	Strategies and Facility Design for Commercial Stage Manufacturing – End-to-End Solutions	Current Pipeline Updates
10:15	The Evolution of Analytics in CAR-T Cell Therapy CAR-T cell therapy is quickly emerging as an approach that has the potential to be a curative treatment for myriad oncology indications. As this immunotherapy advances in the industry, the analytical tools that exist to determine and track critical quality attributes (CQA) must evolve alongside the treatment. Recent advances in the manufacturing processes have led to improved analytical methods that can measure and track CQA with higher accuracy and reliability. Amgen is positioning itself to be a leader in cell and gene therapy, and as part of this effort we will discuss the next generation of analytical approaches that need to evolve to supplement a better understanding of products. Tariq Warsi, Senior Scientist, Process Development, Amgen, USA	A Forward Look at the Future of Cell Therapy Manufacturing • What does the future of manufacturing look like? • Review of different technologies out there • Where do the gaps lie? Donna Rill, Vice President of Manufacturing, Cell Medica Inc	CASE STUDY: Nohla Therapeutics Colleen Delaney, Founder and Chief Medical Officer, Nohla Therapeutics, USA

	Bioprocessing	Commercialization	Pre-clinical and Clinical Development for Cell and Gene Therapies
	Monitoring Quality Across the Process – Process and Automated Analytics for Cell Therapies	Strategies and Facility Design for Commercial Stage Manufacturing – End-to-End Solutions	Current Pipeline Updates
10:35	Analytical Method Establishment and Qualification <ul style="list-style-type: none"> • What type of qualification activities are appropriate • What will this look like when the method is validated further along in the process? • Specific case studies Ruti Goldberg , QC Validation Manager, <i>Pluristem, Israel</i>	Implementation of an Affordable and Scalable Manufacturing Strategy <ul style="list-style-type: none"> • Case study Jon Gunther , Associate Director Technology Strategy and Innovation, <i>Juno Therapeutics, USA</i>	T Lymphocyte Targeting Strategies: CAR-T and TCR-T Success Challenges and Path Forward <ul style="list-style-type: none"> • Status to the current field of T lymphocyte adoptive cell therapy • Current opportunities and challenges • Comparison of CAR-T vs TCR-T • Future perspectives Miguel Forte , CEO, <i>Zelluna Immunotherapy, Norway</i>
10:55	New Analytical Technologies for Facilitating Qbd in Process Analytics <ul style="list-style-type: none"> • Product profiling • A look at product potency and functionality Junxia Wang , Director, Analytical Development, <i>Mustang Bio Inc., USA</i>	PANEL DISCUSSION: What Can Cell Therapy Manufacturers Learn from MAbs to Save Time and Money on the Path to Commercial Scale Manufacturing <p>Knect365 is looking for a mix of both cell and Mab manufacturers to join the discussion panel looking at:</p> <ul style="list-style-type: none"> • Where current gaps lie in cell therapy manufacturing – do Mab manufacturers have advice on how to fill these • What technologies and process improvements can the cell therapy industry take away from their counterparts • Feedback and discussion on how to improve current processes Trent Munro , Executive Director, Process Development, <i>Amgen Inc., USA</i> Lan Cao , Senior Director, Cell Therapy Head of Product Development and Clinical Manufacturing, <i>Takeda Pharmaceuticals International Co., USA</i>	Pre-clinical and Clinical Development of a Next Generation Stromal Cell Therapy Larry Couture , CEO, <i>Orbsen Therapeutics, USA</i>
11:15	Improving Confidence in Cell Therapy Analytical Methods: When Cell Counts Count <p>Analytical methods are essential for establishing quality attributes of cell-based products and for monitoring key steps in the manufacturing process. Measurement assurance strategies and standards for cell therapy product characterization have been increasingly recognized for their critical roles in streamlining efforts in R&D, translation, manufacturing and regulatory submissions. Discussions are underway within various standards development organizations to develop standards to ensure quality, consistency and measurement confidence for cell-based products. Cell count is a fundamental measurement for cell therapy products, underpinning quality attributes (e.g. identity, purity, potency) used in characterization. Although performed routinely in laboratories for over a century, this measurement now requires greater confidence and specification to support the development of cell-based products. NIST, in collaboration with other government agencies and industry stakeholders is developing approaches to provide fit-for-purpose measurement assurance strategies, in the form of documentary standards, experimental designs, and control materials to improve cell counting measurements. These strategies can be further extended to other aspects of cell characterization that face similar measurement challenges.</p> Sumona Sarkar , Biomedical Engineer, <i>NIST, USA</i>		
Technology Workshops			
11:50	Use this event to raise your corporate profile and demonstrate your products and services to our targeted, multidisciplinary audience. By joining us in sponsoring and exhibiting at this event, you will be able to: <ul style="list-style-type: none"> • Use an exhibition stand to meet new clients in the main networking area • Raise your corporate profile and shape your corporate image with logo placement • Ensure market presence as a thought leader with a speaking position For sponsorship and exhibition opportunities please contact: Jennifer Wickett , Tel: +1 857 504 6694; Email: jennifer.wickett@knect365.com		
12:20	<i>Networking Luncheon in the Biotech Week Boston Poster & Exhibit Hall</i>		

	Bioprocessing	Commercialization	Pre-clinical and Clinical Development for Cell and Gene Therapies
	Spotlight Presentations		
1:05	<p>For sponsorship and exhibition opportunities please contact: Jennifer Wickett, Tel: +1 857 504 6694; Email: jennifer.wickett@knect365.com</p>	<p>For sponsorship and exhibition opportunities please contact: Jennifer Wickett, Tel: +1 857 504 6694; Email: jennifer.wickett@knect365.com</p>	<p>An Analytical Method for Determining Bioequivalence of Extracellular Vesicles from Cardiosphere-Derived Cells Translating Extracellular Vesicles (EVs) to the clinic requires the development of potency assays to evaluate the equivalence of the products obtained. EVs obtained from Cardiosphere-derived cells (CDCs) have protective, regenerative, and immunomodulatory effects in animal models. We evaluated the immunomodulatory role of EVs from CDCs and mesenchymal stem cell (MSC) and demonstrated that CDC-EVs polarize macrophage toward an anti-inflammatory phenotype and reduce macrophage recruitment after an acute insult. We also identified a RNA cargo set that differentiates them from MSC-EVs. Using this unique RNA profile, we propose an in vitro analytical method for determining the immunomodulatory potential of different CDC donors. Kiel Peck, Associate Director Product Development, Capricor Therapeutics, Inc., USA</p>
	Analytics Associated with Cell and Gene Therapy Bioprocessing – Process Modelling and Design Space		Current Pipeline Updates
1:25	<p>Combination of Analytical Methods for Characterization of Viral Vectors</p> <ul style="list-style-type: none"> • New combinations of analytical methods used in development and production of Lentiviral vectors for gene therapy • Performance of Lentiviral quantification with molecular methods <p>Gillian Payne, Director, Vector Analytics, bluebird bio, USA</p>		<p>Marrow Infiltrating Lymphocytes (MILs): Adoptive T Cell Therapy from a Road Less Travelled By We have developed a method to isolate, activate and expand bone marrow T cells, the product of which we call MILs. While having some similarities to other types of adoptive T cell therapy we believe our product is unique relative to other products currently being developed by virtue of the fact that MILs are the only adoptive T cell therapy where the cells are both inherently tumor-specific and of a central memory phenotype. Herein we will describe the distinctive properties of MILs, how we have used them in multiple myeloma and other hematologic malignancies, how we plan to use them for solid cancer indications and finally how they may serve as a platform cell for genetic modification. Kimberly A. Noonan, Ph.D., MPH, Co-Founder and CSO, WindMIL Therapeutics, Inc., USA</p>
1:55	<p>Interference by Host Cell Chromatin Depresses Efficiency of AAV Purification This presentation will demonstrate the major pathways by which residual chromatin from host cells interferes with purification of all biologics produced by cell culture, and particularly with AAV. Examples will be shared how to manage chromatin contamination to achieve more effective and more economical processes. Peter Gagnon, Chief Scientific Officer, BIA Separations, Slovenia</p>	<p>Spotlight Presentations</p> <p>Use this event to raise your corporate profile and demonstrate your products and services to our targeted, multidisciplinary audience. By joining us in sponsoring and exhibiting at this event, you will be able to:</p> <ul style="list-style-type: none"> • Use an exhibition stand to meet new clients in the main networking area • Raise your corporate profile and shape your corporate image with logo placement • Ensure market presence as a thought leader with a speaking position <p>For sponsorship and exhibition opportunities please contact: Jennifer Wickett, Tel: +1 857 504 6694; Email: jennifer.wickett@knect365.com</p>	
2:25	<i>Networking Refreshment Break in the Biotech Week Boston Poster & Exhibit Hall</i>		
	BWB KEYNOTE SESSION		
2:45	<p>High-Impact Ideas and Use-Inspired Research...a chat with MIT's Bob Langer on How to Create Innovations That Matter Dr. Robert Langer, Sc.D., David H. Koch Institute Professor, Koch Institute of Integrative Cancer Research, Massachusetts Institute of Technology</p>		
3:30	<p>Driving Value with Process and Facility Intensification: Moving from Current- to Next- Generation Bioprocessing E. Morrey Atkinson, VP/Head of Internal Commercial Manufacturing, Bristol-Myers Squibb, USA</p>		
4:15	<p>The Complex World of Biosimilar Process Development Elsie DeBella, Vice President, Biologics Process and CMC Development, Momenta Pharmaceuticals</p>		
4:45	<i>Grand Opening of the Poster & Exhibit Hall and Cocktail Reception</i>		
6:30	<i>End of Day One</i>		

7:00	<i>Registration and Coffee</i>		
	PLENARY SESSION		
8:00	Chairperson's Remarks		
	Regulatory Updates and Recent Progress: US, Japan and EU		
8:05	It Depends: Understanding the Science and History behind the Regulations Nancy Markovitz, Assoc. Director, Regulatory Affairs CMC, Nantkwest, USA		
8:35	Breakfast Surgery – FDA, EMA and PMDA Pinch Points Knect365 is looking for 5-6 panellists, comprised of suppliers, manufacturers and regulators to join this breakfast surgery. Attendees will have the opportunity to submit their 'pinch' points anonymously to the panel in advance and this session will provide the perfect opportunity to hear from the experts on expectations. Topics to be covered include: <ul style="list-style-type: none"> • IND's and BLA's – expectations • Raw materials and viral safety considerations • Autologous therapies – who should take the burden? The manufacturer or the supplier? • CE marking • Process development and new process implementation – what do the regulators think? • Analytics and CMC – Potency assays, comparability etc. 		
	Spotlight Presentation		
9:25	Use this event to raise your corporate profile and demonstrate your products and services to our targeted, multidisciplinary audience. By joining us in sponsoring and exhibiting at this event, you will be able to: <ul style="list-style-type: none"> • Use an exhibition stand to meet new clients in the main networking area • Raise your corporate profile and shape your corporate image with logo placement • Ensure market presence as a thought leader with a speaking position For sponsorship and exhibition opportunities please contact: Jennifer Wickett, Tel: +1 857 504 6694; Email: jennifer.wickett@knect365.com		
9:45	<i>Networking Refreshment Break in the Biotech Week Boston Poster & Exhibit Hall</i>		
	Bioprocessing	Commercialization	Pre-clinical and Clinical Development
10:10	Chairperson's Remarks Jon A. Rowley, Founder & Chief Technology Officer, RoosterBio, Inc., USA	Chairperson's Remarks	Chairperson's Remarks
	Process Automation and Closed Systems – Applications and Case Studies	Internal Vs. External Manufacturing and CMO/CDMO Management throughout Development Lifecycle	Process Validation and Supply Chain Strategies in the Clinic
10:30	Adopting Various Manufacturing Closed Systems to Gene Modified T Cell Therapies <ul style="list-style-type: none"> • Immatix developed a proprietary tumor antigen targets discovery platform, XPRESIDENT® • The platform identifies novel tumor-specific targets and TCR candidate. It also screens TCR candidates based on these targets against off-target toxicities in absence of reliable in vivo models • Natural and engineered TCRs against these tumor targets have been used in various Immatix' Adoptive Cellular Therapy programs in "First In Man" clinical trials • Extensive process development was carried out using primary T cells derived from multiple healthy donors and cancer patients to optimize each step in the manufacturing of TCR T cells for 3 clinical trials (IMA101, IMA201, IMA202, and IMA203) • Manufacturing for engineered TCR T cell therapies has been adapted into 3 different closed systems with for future phases of clinical trials with excellent results Ali Mohamed, VP, CMC, Immatix, USA	DUAL DIALOGUE: When to Make the Decision to Either Insource or Outsource Talk One: Becoming Cell Therapy Makers - Opportunities And Challenges In "In House" Manufacturing of Cell Therapy Products Lior Raviv, Vice President Development, Pluristem, Israel	The Balancing Act: Engineering vs. Tinkering Platform Processes with GMP Manufacturing in Mind At Adverum, our focus is on bringing innovation to patients in need. With that mindset, we are leveraging our next-generation adeno-associated virus (AAV)-based directed evolution platform to identify and develop new therapies. Within Process Development, we have built an adaptable platform process that works across multiple therapeutic constructs, at varying scales. As we continue to develop new products, we are assessing new technologies to refine and improve our platform, while preserving aspects that enable versatility. In this talk, we will review aspects of our platform process and provide insight into potential changes that are under consideration, based on our scale-up experiences. Pratik Jaluria, Executive Director, Process Development and Manufacturing, Adverum, USA

	Bioprocessing	Commercialization	Pre-clinical and Clinical Development for Cell and Gene Therapies
	Monitoring Quality Across the Process – Process and Automated Analytics for Cell Therapies	Internal Vs. External Manufacturing and CMO/CDMO Management throughout Development Lifecycle	Process Validation and Supply Chain Strategies in the Clinic
11:00	The Economics of Closed Systems – Ensuring Reproducibility <ul style="list-style-type: none"> • How can showing reproducibility then lead to a more economical scale up or out process? • Using closed systems to make facilities more economical • How does having a closed system impact autologous manufacturing and how does this affect the design of the plant? Ohad Karnieli, CEO & Co-Founder, ATVIO Biotech, Israel	DUAL DIALOGUE (continued): When to Make the Decision to Either Insource or Outsource Talk Two: Phase-Appropriate Manufacturing - Finding the Right Balance Between Internal and External Manufacturing as a Cell Therapy Company Grows Chris Gemmiti, VP Operations, Sentien Biotechnologies, Inc., USA	Developing a Scaled Process for Manufacturing Stem Cell Derived Islets <ul style="list-style-type: none"> • ESCs as starting material, allogeneic approach, selection of clinical line • Differentiation optimization Scale-up to bioreactors • Raw materials for cGMP manufacturing (evaluation, cost, supply chain) • Path to commercialization Austin Thiel, Senior Principal Scientist, Semma Therapeutics, USA
11:30	AUTOMATION EXPERT PANEL Knect365 is looking for 5 speakers to join our expert led discussion panel to talk on the below topics: <ul style="list-style-type: none"> • Case studies/feedback on closed systems in general • Is there a need to have closed systems in clean rooms? • Process automated sampling • What can we learn from automation for MABs? • How do you make things connectable between different devices? • Automation linked to cost of goods Ohad Karnieli, CEO & Co-Founder, ATVIO Biotech, Israel Ali Mohamed, VP, CMC, Immatic, USA Lior Raviv, Vice President Development, Pluristem, Israel Tristan Thwaites, Lead Technical Scientist, Cell and Gene Therapy Catapult, UK Tamara Monesmith, Senior Director, Cellular Process Development, Editas Medicine, USA	Capabilities of blood centres and banks – Could they be CMO's of the future? <ul style="list-style-type: none"> • What are the capabilities of blood centres and the blood banking industries? • What is the leverage for them to become CMO's? • What changes need to be made to infrastructure to make this happen? Wouter Van t'Hof, Cord Blood Bank Director, Cleveland Cord Blood Centre, USA	Ensuring Enough Supply and Magnitude in Terms of Patient and Dose Increases Someet Narang, Senior Scientist, MedImmune, USA
Spotlight Presentations			
12:05	Use this event to raise your corporate profile and demonstrate your products and services to our targeted, multidisciplinary audience. By joining us in sponsoring and exhibiting at this event, you will be able to: <ul style="list-style-type: none"> • Use an exhibition stand to meet new clients in the main networking area • Raise your corporate profile and shape your corporate image with logo placement • Ensure market presence as a thought leader with a speaking position For sponsorship and exhibition opportunities please contact: Jennifer Wickett, Tel: +1 857 504 6694; Email: jennifer.wickett@knect365.com		Use this event to raise your corporate profile and demonstrate your products and services to our targeted, multidisciplinary audience. By joining us in sponsoring and exhibiting at this event, you will be able to: <ul style="list-style-type: none"> • Use an exhibition stand to meet new clients in the main networking area • Raise your corporate profile and shape your corporate image with logo placement • Ensure market presence as a thought leader with a speaking position For sponsorship and exhibition opportunities please contact: Jennifer Wickett, Tel: +1 857 504 6694; Email: jennifer.wickett@knect365.com
12:35	<i>Networking Luncheon in the Biotech Week Boston Poster & Exhibit Hall</i>		

	Bioprocessing	Commercialization	Pre-clinical and Clinical Development for Cell and Gene Therapies
	Reducing the Cost of Manufacturing – Costs of Goods Calculations and Considerations	Internal Vs. External Manufacturing and CMO/CDMO Management throughout Development Lifecycle	Collaboration for End-to- End Solutions in Preclinical and Clinical Research
1:40	<p>Dual Dialogue: Cost of Goods Calculations for Cell Therapy Products</p> <p>Knect365 is looking for 2 speakers to present back to back on carrying out cost of goods calculations when manufacturing cell therapy products</p> <ul style="list-style-type: none"> • Case studies <p>Talk One: Better Processes with “Better” Cells – Engineering Cells for Enhanced Manufacturability.</p> <p>While much of the focus of gene engineering in the CGT field is on therapeutic activities, synthetic biology presents a significant opportunity to augment our approaches to cell manufacturing. How might we employ cell engineering strategies to improve product quality, reduce COGs, or better understand and control our manufacturing processes?</p> <p>Nick Timmins, VP Process Sciences, BlueRock Therapeutics, <i>Canada</i></p> <p>Talk Two: TBA</p> <p>Boaz Leshem, Vice President, Operations and Manufacturing, Pluristem, <i>Israel</i></p>	<p>CDMO Expert Led Panel: How Do You Choose Your Development Partner?</p> <ul style="list-style-type: none"> • How do you choose your CDMO • What capabilities should they have? • Centralised manufacturing • Regional manufacturing • Local manufacturing • Considerations for autologous, allogeneic and gene therapy products • Tech transfer of processes to new facilities <p><i>Confirmed speakers:</i></p> <p>Chris Gemmiti, VP Operations, Sentien Biotechnologies, Inc., USA</p> <p>Lior Raviv, Vice President Development, Pluristem, Israel</p> <p>David Peritt, Chief Technology Officer, Sigilon Therapeutics, USA</p> <p>Wouter Van t’Hof, Cord Blood Bank Director, Cleveland Cord Blood Centre, USA</p>	<p>CASE STUDIES: Low Cost Automation to Drive Efficiency and Reproducibility</p> <p>In basic and preclinical research associated with cell therapy, most cell processing is performed manually, straining resources as well as posing challenges in reproducibility and consistency. With dendritic cell based therapies as the context, several case studies will be presented to illustrate how simple automation solutions can overcome these constraints as well as help optimize future larger scale process development.</p> <p>Shashi Murthy, Professor of Chemical Engineering, Northeastern University, USA</p>
2:10		<p>Facility Design and Flexibility for Efficient Cell Therapy Manufacturing</p>	<p>Leveraging Academic and Commercial Contract Manufacturing Organizations to Facilitate Accelerated FDA Approvals</p> <p>The 21st Century Cures Act and the FDA mandate for accelerating the approval process for cellular therapies has impact on the approach to GMP manufacturing for early phase clinical trials. We have embraced an academic and industry partnership to facilitate multicenter clinical trials using Tumor Infiltrating Lymphocytes (TIL) and CAR-T cells for liquid and solid tumors. Through a combination of process improvements intended to shorten product manufacturing time, as well as innovative implementation of GMP practices, we have maximized the contribution of academic and contract manufacturing organizations to support multiple on-going trials intended to receive accelerated FDA approval for a new cellular therapy.</p> <p>Linda Kelley, Senior Member, Director Cell Therapy Facility, Moffitt Cancer Center, USA</p>
	Technology Workshops		
2:40	<p>Use this event to raise your corporate profile and demonstrate your products and services to our targeted, multidisciplinary audience. By joining us in sponsoring and exhibiting at this event, you will be able to:</p> <ul style="list-style-type: none"> • Use an exhibition stand to meet new clients in the main networking area • Raise your corporate profile and shape your corporate image with logo placement • Ensure market presence as a thought leader with a speaking position <p>For sponsorship and exhibition opportunities please contact: Jennifer Wickett, Tel: +1 857 504 6694; Email: jennifer.wickett@knect365.com</p>		
3:10	<i>Networking Refreshment Break in the Biotech Week Boston Poster & Exhibit Hall</i>		

	Bioprocessing	Commercialization	Pre-clinical and Clinical Development for Cell and Gene Therapies
3:40	Spotlight Presentations		
	For sponsorship and exhibition opportunities please contact: Jennifer Wickett, Tel: +1 857 504 6694; Email: jennifer.wickett@knect365.com	For sponsorship and exhibition opportunities please contact: Jennifer Wickett, Tel: +1 857 504 6694; Email: jennifer.wickett@knect365.com	For sponsorship and exhibition opportunities please contact: Jennifer Wickett, Tel: +1 857 504 6694; Email: jennifer.wickett@knect365.com
4:00	Meeting the Challenge of Delivering Autologous Therapies in the Commercial Sector <ul style="list-style-type: none"> • Case study • What is the future for autologous therapies? • Are they commercially viable • What are the strategies for ensuring that they are? 	Developing a Commercially-Ready Process for Viral Vector Manufacturing <ul style="list-style-type: none"> •What can we apply from the 30+ years of biologics manufacturing? •Strategies for developing a validation plan •Leveraging platforms to provide manufacturing efficiencies •Supply of raw materials and viral banks for low cadence products John Kerwin, Manufacturing Scientist, Gene Therapy, Biogen, USA	Current State of Play for the Cell Therapy Industry in the Clinic – Stats and Facts Patricia Reilly, Vice President of Intelligence Alliances and Product Unification, Pharma Intelligence, Informa, USA
4:30	Delivering New Investigational Medicinal Products to the Clinic Through Next-Generation Allogeneic Cell Therapies Bryan D. Utter, Procurement Manager, GMP Solutions, Cellectis Inc., USA	Strategies to Deliver Scalable and Reliable Lentiviral Vector Biomanufacturing Large-scale clinical production of lentiviral vectors (LV) using current good manufacturing practice (cGMP) methods comes with significant challenges. We have established the Cytegrity™ stable cell line system for LV bioproduction and have defined key process, quality and regulatory parameters needed to achieve desired productivity and quality across multiples scales and different bioproduction systems. This approach has allowed scalable bioproduction of LV required for Phase I and II clinical trials, while paving the way for future commercialization. Jeffrey S. Bartlett, Chief Scientific Officer, Senior Vice President, Research and Development, Calimmune, Inc., USA	What Academia are Looking for in a Development Partner <ul style="list-style-type: none"> • Case study • What are academia doing the research looking for in a business partner? • How can these partnerships work to drive success? Olive J Sturtevant, Administrative Director of Connell & O'Reilly Families, Cell Manipulation Core Facility, Dana Farber Cancer Institute
5:00	The Next Wave of Cell Therapy Product – Allogeneic Manufacturing Solutions <ul style="list-style-type: none"> • Strategies for manufacturing an 'off the shelf' product • Regulatory perspectives on this • How can you ensure large batch sizes • Scaling out solutions Yajin (Jenny) Ni, Associate Research Fellow, Director Manufacturing Process Development Lead, Allogene Therapeutics, Inc., USA	Solving Challenges in Lentiviral Vector Manufacturing For a long time commercial scale viral vector manufacturing was a bottleneck in the field. Biggest challenges were related to those vectors, such as lentiviral vectors, requiring plasmid transfection of adherent cells in big volumes. We have developed a commercial scale lentiviral vector manufacturing process utilizing PEIpro® based four plasmid transfection and the iCELLis® fixed-bed bioreactor for adherent 293T cells. iCELLis Nano (2.67-4 m ²) was used for optimizing several production parameters for scale-up. For scalable LV production, perfusion rate control by measuring cell metabolite concentrations in the bioreactor leads to higher productivity and reduced costs. Optimization of transfection conditions, cell seeding density for targeted cell concentration during transfection, use of low compaction fixed-bed and lowering the culture pH have a positive effect on LV productivity. Developed process was scaled up into iCELLis500 and were able to show the real commercial scale lentiviral vector manufacturing in commercial scale yielding >10 ¹⁶ viral particles. Commercial scale upstream process development was followed by development of scalable downstream process. Virus containing medium was harvested by perfusion, concentrated and diafiltrated by tangential flow filtration and virus was purified using anion exchange chromatography. These results show for the first time that plasmid transfection of adherent cells in iCELLis bioreactor is scalable from bench level to clinical scale LV production. Hanna Leinonen, Senior Scientist, Kuopio Center for Gene and Cell Therapy, Finland	DISCUSSION PANEL: Driving Collaboration for Development In Cell and Gene Therapy Linda Kelley, Senior Member, Director Cell Therapy Facility, Moffitt Cancer Center, USA Olive J Sturtevant, Administrative Director of Connell & O'Reilly Families, Cell Manipulation Core Facility, Dana Farber Cancer Institute
5:30	<i>Cocktail Reception in the Poster & Exhibition Hall</i>		
6:30	<i>End of Day Two</i>		

7:00	<i>Registration and Coffee</i>
	CELL THERAPY BIOPROCESSING AND COMMERCIALIZATION
7:55	Chairperson's Remarks Erik J. Woods, Co-Founder and Chief Science Officer, Ossium Health, Inc., USA
	Logistics, Supply Chain, and Cryopreservation Techniques
8:00	<p style="text-align: center;">Cryopreservation Can Reduce Variability at Multiple Steps During the Manufacturing of Cell Therapies</p> <p>Pluripotent stem cells (PSCs) can be directed into any cell type in the adult body. BlueRock Therapeutics is making the next generation of cellular medicines by converting PSCs into allogenic cell therapies through the timely manipulation of signaling pathways in ways that mimic human development. The power of PSC biology comes at the expense of complexity which complicates bioprocess. Cryopreservation can be leveraged to "time-shift" the use of biomass, removing a variable that can cause drug product, assay and manufacturing variability. Here, I will highlight strategies to reduce variability through cryopreservation and identify challenges in implementing such approaches.</p> <p style="text-align: center;">Mark J. Tomishima, Senior Director, BlueRock Therapeutics, Canada</p>
8:30	<p>Cryopreservation: A Critical Tool for MSC Translation</p> <p>James Ankrum, Assistant Professor, Biomedical Engineering, The University of Iowa, USA</p>
9:00	A presentation from Savsu Technologies
9:30	<i>Networking Refreshment Break in the Biotech Week Boston Poster & Exhibit Hall</i>
	Vein-to Vein Supply Chain and Transportation Considerations
10:15	<p style="text-align: center;">Transportation Strategies from Manufacture to the Patient: Elevating Bottle Necks</p> <ul style="list-style-type: none"> • Logistics of the transfer from manufacture to patient • Current systems used for transport/cryogenically freezing • Preparing samples for use • Systems used to track shipments • What improvements can be made • Storage and packaging
10:45	<p>Understanding the Regulatory Requirements of Sample Handling</p> <ul style="list-style-type: none"> • What are the specific handling requirements from regulators? • How do you meet the documentation and regulatory compliance for storage?
11:15	<p style="text-align: center;">LOGISTICS ROUND-TABLES: Analyzing where the Gaps Lie</p> <p>Knect365 is looking for 4 round-table leaders to host round-tables on the below topics:</p> <ul style="list-style-type: none"> • Product distribution • Injection technologies/ Administration techniques • Thawing technologies • Global supply chain strategies (including raw materials) • Forward thinking and preparations for commercialisation
	Technology Workshops
11:45	
12:15	<i>Networking Luncheon in the Biotech Week Boston Poster & Exhibit Hall</i>

LOGISTICS, SUPPLY CHAIN, AND CRYOPRESERVATION TECHNIQUES

1:30

CASE STUDY: Best Practice for Managing Particulates and Visible Inspections

Erik J. Woods, Co-Founder and Chief Science Officer, Ossium Health, Inc., USA

2:00

Leachable Profiles of Final Product Containers

A representative from VR Analytical

Managing the Chain of Identity in Cell Therapeutics Manufacturing – Supply Chain Security

2:30

Implementation of Technologies and Workflows to Achieve High Quality Patient Specific Batches

- Improving chain of identity
- Reduction of errors caused by manual procedures

Jian Irish, Senior Vice President, Supply Chain, Kite Pharma, USA

3:00

Chairpersons Closing Remarks


3:10

End of Conference


THE CELL & GENE THERAPY AUDIENCE

By participating in this year's event, you will gain unparalleled access and exposure to key decision makers.

ATTENDEES BY TITLE



GEOGRAPHY



SPONSORS:

Session Sponsors:

Technology Workshop Sponsors:

Bronze Sponsor:

Support Sponsor:

EXHIBITORS:

- Aldevron
- Aseptic Technologies
- BIA Separations
- Bionique
- BioSpherix
- Fresenius Kabi
- PBS Biotech
- Quad Technologies
- Roche Custom Biotech
- Texcell
- Waisman
- Biomufacturing